Arbutus Biopharma Corp (NASDAQ:ABUS) price target raised to $11.50 by B. Riley

Analyst Ratings For Arbutus Biopharma Corp (NASDAQ:ABUS)

Story continues below

Today, B. Riley raised its price target on Arbutus Biopharma Corp (NASDAQ:ABUS) to $11.50 per share.

There are 3 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Arbutus Biopharma Corp (NASDAQ:ABUS) is Hold with a consensus target price of $9.50 per share, a potential 2.06% downside.

Some recent analyst ratings include

  • 7/16/2018-Arbutus Biopharma Corp (NASDAQ:ABUS) had its Buy rating reiterated by Chardan Capital with a $11.00 price target
  • 11/7/2017-Arbutus Biopharma Corp (NASDAQ:ABUS) had its Market Perform rating reiterated by Leerink Swann with a $5.00 price target
  • 10/4/2017-Arbutus Biopharma Corp (NASDAQ:ABUS) had its Outperform rating reiterated by JMP Securities with a $13.00 price target
  • 6/2/2017-Arbutus Biopharma Corp (NASDAQ:ABUS) has coverage initiated with a Buy rating and $32.00 price target
  • 1/9/2017-Arbutus Biopharma Corp (NASDAQ:ABUS) gets upgraded to Buy by Bloom Burton

    About Arbutus Biopharma Corp (NASDAQ:ABUS)
    Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to block production of HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also include AB-423, a core protein inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection; and AB-452, an HBV RNA Destabilizer, which is in preclinical study. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates comprising N-Acetylgalactosamine conjugate technology, cccDNA targeting agents, and checkpoint inhibition. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) that has been completed Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and RNA-based neoantigen immunotherapy products. The company has strategic alliance, licensing, and research collaboration agreements with Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Marina Biotech Inc.; U.S. National Institutes of Health; and The Baruch S. Blumberg Institute and Drexel University. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

    Recent Trading Activity for Arbutus Biopharma Corp (NASDAQ:ABUS)
    Shares of Arbutus Biopharma Corp closed the previous trading session at 9,35 −0,100 1,06 % with 9.7 shares trading hands.

    An ad to help with our costs